An international phase 3 clinical trial that treated patients with high-risk localized and locally advanced prostate cancer ...
An international phase 3 clinical trial that treated patients with high-risk localized and locally advanced prostate cancer ...
Adding darolutamide to standard treatment for aggressive prostate cancer reduced the risk of the disease spreading in an ...
An international phase 3 clinical trial that treated patients with high-risk localized and locally advanced prostate cancer ...
New substudy results showed a 51% lower estimated risk of metastasis or death over time with perioperative apalutamide plus ...
Briganti and colleagues concluded that, together with the main PROTEUS study, the substudy supports 1-year perioperative apalutamide plus ADT as a treatment option for patients with high-risk ...
Johnson & Johnson (NYSE: JNJ) today announced new results from the Phase 3 PROTEUS substudy that directly compared the investigational use of apalutamide plus androgen deprivation therapy (ADT), given ...
Prostate cancer treatments carry different risks. Dr. Fernando Bianco argues for informed decisions that balance cancer ...
Dr. Kishore T. A , Senior Consultant, Uro Oncology & Transplant Surgery, Aster Medcity Kochi | A major 1,500-case experience ...
Five-year results from the NRG-GU003 Phase III trial show that a 25-fraction, five-week postoperative radiation schedule ...
TRACE-I: Long-Term Outcomes of PSMA-Guided Salvage Surgery in Recurrent Prostate Cancer / cancer, cancer care, Cancer ...
Salvage radiation after surgery: If PSA rises after surgery, radiation to the area where the prostate was can still be curative. AUA guidelines recommend offering it while PSA is 0.5 ng/mL or lower, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results